Genomic Health said today that the German Federal Joint Committee (G-BA) has issued a positive repayment choice for its Oncotype DX Breast Recurrence Score test following an end by the German Institute for Quality and Efficiency in Health Care (IQWiG) that there is adequate proof supporting the capacity of the test to guide bosom malignant growth adjuvant chemotherapy choices. Genomic Health has said that the IQWiG evaluation depended on resul....
Tags : Germany, Breast Cancer, Genomic Health, German Federal Joint Committee, German Institute for Quality and Efficiency in Health Care, Oncotype DX Breast Recurrence, HER2-negative, TAILORx, IQWiG,
comments (0)